Here are the studies most positive in HCC according to response rate and disease-free survival:
- Yttrium-90 Radioembolization in Combination with Durvalumab:
- Objective Response Rate (ORR): 83.3% (95% CI, 62.6-95.3) with 7 (29.2%) patients achieving complete response and 13 (54.2%) partial response.
- Progression-Free Survival (PFS): Median PFS of 6.9 months (95% CI, 5.4-15.2).
- Overall Survival (OS): Median OS not reached with 18-month OS rate of 58.3% (95% CI, 36.4-75.0).
- Pencil Beam Scanning Technique of Carbon Ion Radiotherapy (CIRT):
- Overall Survival (OS) Rates: 1-year OS rate at 91.3%, 3-year at 81.9%, and 5-year at 67.1%.
- Local Progression-Free Survival (LPFS) Rates: 1-year LPFS at 100%, 3-year at 94.4%, and 5-year at 94.4%.
- Progression-Free Survival (PFS) Rates: 1-year PFS at 73.6%, 3-year at 59.2%, and 5-year at 37.0%.
- Toripalimab Plus Subtotal Local Ablation:
- Objective Response Rate (ORR): 33.8% with Schedule D3 compared to 16.9% with toripalimab alone.
- Progression-Free Survival (PFS): Improved median PFS of 7.1 months compared to 3.8 months with toripalimab alone.
- Overall Survival (OS): Improved median OS of 18.4 months compared to 13.2 months with toripalimab alone.
These studies highlight the highest objective response rates and substantial disease-free survival benefits among the trials reviewed.